source
- Merck ends Sutro partnership on IL-2 agonist MK-1484 amid routine pipeline prioritizationMerck announced it is discontinuing development of MK-1484, an interleukin-2 agonist created in partnership with Sutro Biopharma. The drug entered clinical testing in 2022 as a monotherapy and in…
- Siemens Healthineers to spin off in‑vitro diagnostics unit as Olyrian Diagnostics, rebranding to HealthineersSiemens Healthineers announced it will separate its in‑vitro diagnostics division into a new standalone company called Olyrian Diagnostics. The carve‑out will run in parallel with a corporate name…